eXoZymes Inc (EXOZ) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the EXOZ SEC filings page.
This page shows eXoZymes Inc (EXOZ) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Development spending and financing-dependent cash use dominate eXoZymes' reported economics more than its limited revenue base.
At the only period with reported revenue, FY2023, R&D was about 7.5x revenue:$527K versus$70K . By FY2025, investment intensity had escalated to$3.7M of R&D while operating cash flow was-$6.5M , indicating a development-led model rather than a scaled commercial engine.
The balance sheet's liquidity cushion narrowed: current ratio fell from 8.1x in FY2024 to 2.5x in FY2025 while debt-to-equity rose from 0.3x to 0.8x. The reported 5.6-month liquidity comparison therefore sits alongside tighter short-term flexibility, even though total liabilities were broadly stable.
FY2024's financing-led funding profile included financing cash flow of
Financial Health Signals
eXoZymes Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
eXoZymes Inc passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
eXoZymes Inc reported a net loss of $9.2M while operations used $6.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
eXoZymes Inc's EBITDA was -$2.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 15.7% from the same quarter a year earlier. Against the prior quarter it is down 24.7%.
eXoZymes Inc reported -$2.9M in net income in Q2 2026. This represents a decrease of 22.0% from the same quarter a year earlier. Against the prior quarter it is down 21.4%.
eXoZymes Inc earned -$0.33 per diluted share (EPS) in Q2 2026. This represents a decrease of 17.9% from the same quarter a year earlier. Against the prior quarter it is down 17.9%.
Not reported for Q2 2026.
Cash & Balance Sheet
eXoZymes Inc recorded an outflow of $1.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 3.3% from the same quarter a year earlier. Against the prior quarter it is down 3.7%.
eXoZymes Inc held $5.7M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
eXoZymes Inc's ROE was -78.8% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 46.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 76.3 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
eXoZymes Inc invested $1.4M in research and development in Q2 2026. This represents an increase of 79.1% from the same quarter a year earlier. Against the prior quarter it is up 28.3%.
eXoZymes Inc invested $1 in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.
Not reported for Q2 2026.
EXOZ Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $1.4M+79.1% | $1.1M+95.0% | N/A | $1.2M+68.2% | $803K+238.3% | $575K+107.2% | N/A | $723K+2489.8% |
| SG&A Expenses | $1.5M-13.1% | $1.3M-8.0% | N/A | $1.3M+47.0% | $1.7M+59.9% | $1.4M+88.2% | N/A | $888K+144.1% |
| Operating Income | -$3.0M-15.9% | -$2.4M-22.4% | N/A | -$2.5M-56.5% | -$2.5M-91.8% | -$2.0M-93.4% | N/A | -$1.6M-311.3% |
| EBITDA | -$2.9M-15.7% | -$2.3M-22.3% | N/A | -$2.4M-58.2% | -$2.5M-96.4% | -$1.9M-98.8% | N/A | -$1.5M-351.0% |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $45K |
| Net Income | -$2.9M-22.0% | -$2.4M-27.7% | N/A | -$2.3M-38.1% | -$2.4M-73.5% | -$1.9M-84.1% | N/A | -$1.7M-218.2% |
| EPS (Basic) | -$0.33-17.9% | -$0.28-27.3% | -$0.31-24.0% | -$0.270.0% | -$0.28-27.3% | -$0.22-37.5% | -$0.25-38.9% | -$0.27-237.5% |
| EPS (Diluted) | -$0.33-17.9% | -$0.28-27.3% | -$0.31-24.0% | -$0.270.0% | -$0.28-27.3% | -$0.22-37.5% | -$0.25-38.9% | -$0.27-237.5% |
| Diluted Shares (Avg) | 9M+3.4% | 8M+1.1% | N/A | 8M+34.1% | 8M+34.0% | 8M+33.9% | N/A | 6M0.0% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
EXOZ Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $8.0M-17.5% | $4.0M-65.1% | $6.0M-54.2% | $7.7M+116.8% | $9.7M | $11.5M | $13.0M+266.3% | $3.6M |
| Current Assets | $6.2M-18.1% | $2.1M-77.8% | $3.9M-63.6% | $5.6M+294.1% | $7.5M | $9.4M | $10.8M+791.6% | $1.4M |
| Cash & Equivalents | $5.7M-19.1% | $1.4M-83.0% | $3.0M-68.7% | $5.1M+2079.5% | $7.0M+4314.8% | $8.5M+7379.6% | $9.7M+14508.3% | $234K-50.7% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $4.3M+77.3% | $2.5M-5.8% | $2.6M-1.5% | $2.3M-67.3% | $2.4M | $2.6M | $2.6M-33.7% | $7.2M |
| Current Liabilities | $1.6M+33.0% | $1.6M+9.6% | $1.6M+17.5% | $1.2M-78.7% | $1.2M | $1.4M | $1.3M-44.8% | $5.8M |
| Non-Current Liabilities | $2.7M+121.4% | $908K-24.3% | $1.0M-21.3% | $1.1M-18.6% | $1.2M | $1.2M | $1.3M-16.2% | $1.4M |
| Total Equity | $3.7M-49.5% | $1.5M-82.8% | $3.4M-67.4% | $5.4M+249.2% | $7.2M+419.8% | $8.9M+810.5% | $10.4M+2811.5% | -$3.6M-693.2% |
| Retained Earnings | -$26.4M-63.1% | -$23.5M-70.1% | -$21.1M-76.7% | -$18.4M-82.5% | -$16.2M | -$13.8M | -$11.9M-96.3% | -$10.1M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
EXOZ Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.6M-6.7% | -$1.5M-34.5% | -$2.0M+65.4% | -$1.9M-242.9% | -$1.5M+39.4% | -$1.1M-503.1% | -$5.7M-628.7% | -$542K |
| Depreciation & Amortization | $88K+22.2% | $88K+25.0% | $84K+24.5% | $82K+19.0% | $72K+6.0% | $71K+12.3% | $68K+14.6% | $69K+38.5% |
| Stock-Based Compensation | N/A | $501K+57.9% | N/A | N/A | N/A | $317K+122.2% | N/A | N/A |
| Capital Expenditures | -$1-100.0% | $58K+85.5% | $75K-64.4% | $13K | $51K+35.8% | $31K-79.1% | $210K+91.7% | $0 |
| Free Cash Flow | -$1.6M-3.3% | -$1.6M-35.8% | -$2.0M+65.4% | -$1.9M-245.3% | -$1.6M+38.3% | -$1.2M-979.7% | -$5.9M-562.7% | -$542K |
| Investing Cash Flow | $1+100.0% | -$58K-85.5% | -$75K+64.4% | -$13K-143.1% | -$31K+17.1% | -$31K+78.2% | -$210K-91.7% | $31K |
| Financing Cash Flow | $5.8M | -$13K+70.6% | -$11K-100.1% | N/A | N/A | -$43K+52.7% | $15.4M+3075.9% | $586K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
EXOZ Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -78.8%-46.2pp | -155.1%-134.2pp | N/A | -42.5% | -32.6% | -20.9% | N/A | N/A |
| Return on Assets | -36.1%-11.7pp | -59.0%-42.9pp | N/A | -29.6%+16.9pp | -24.4% | -16.1% | N/A | -46.5% |
| Current Ratio | 3.81-2.4x | 1.32-5.2x | 2.51-5.6x | 4.53+4.3x | 6.19 | 6.52 | 8.12+7.6x | 0.25 |
| Debt-to-Equity | 1.18+0.8x | 1.63+1.3x | 0.76+0.5x | 0.44 | 0.34 | 0.30 | 0.25 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| eXoZymes Inc EXOZ | FY2025 | N/A | -$9.2M | N/A | $57.3M | — |
| Adagene Inc. ADAG | FY2025 | $7.7M | -$17.6M | N/A | $222.2M | 62/100 |
| Vistagen Therapeutics Inc VTGN | FY2026 | $1.3M | -$69.7M | N/A | $10.5M | 51/100 |
| Armata Pharmctcl ARMP | FY2025 | N/A | -$173.8M | N/A | $194.5M | — |
| Tscan Therapeutics, Inc. TCRX | FY2025 | $10.3M | -$129.8M | N/A | $21.5M | 38/100 |
| Fate Therapeutic FATE | FY2025 | $6.6M | -$136.3M | N/A | $279.2M | 53/100 |
Where eXoZymes Inc Ranks
Frequently Asked Questions
Is eXoZymes Inc profitable?
No, eXoZymes Inc (EXOZ) reported a net income of -$9.2M in fiscal year 2025.
What is eXoZymes Inc's EBITDA?
eXoZymes Inc (EXOZ) had EBITDA of -$9.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is eXoZymes Inc's return on equity (ROE)?
eXoZymes Inc (EXOZ) has a return on equity of -269.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is eXoZymes Inc's free cash flow?
eXoZymes Inc (EXOZ) recorded an outflow of $6.7M in free cash flow during fiscal year 2025. This represents a 25.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is eXoZymes Inc's operating cash flow?
eXoZymes Inc (EXOZ) recorded an outflow of $6.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are eXoZymes Inc's total assets?
eXoZymes Inc (EXOZ) had $6.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are eXoZymes Inc's capital expenditures?
eXoZymes Inc (EXOZ) invested $170K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does eXoZymes Inc spend on research and development?
eXoZymes Inc (EXOZ) invested $3.7M in research and development during fiscal year 2025.
What is eXoZymes Inc's current ratio?
eXoZymes Inc (EXOZ) had a current ratio of 2.51 as of fiscal year 2025, which is generally considered healthy.
What is eXoZymes Inc's debt-to-equity ratio?
eXoZymes Inc (EXOZ) had a debt-to-equity ratio of 0.76 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is eXoZymes Inc's return on assets (ROA)?
eXoZymes Inc (EXOZ) had a return on assets of -153.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is eXoZymes Inc's P/E ratio?
eXoZymes Inc (EXOZ) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $57.3M as of Sep 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is eXoZymes Inc's price-to-sales ratio?
eXoZymes Inc (EXOZ) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $57.3M as of Sep 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does eXoZymes Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, eXoZymes Inc (EXOZ) held $3.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $6.5M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is eXoZymes Inc's Piotroski F-Score?
eXoZymes Inc (EXOZ) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are eXoZymes Inc's earnings high quality?
eXoZymes Inc (EXOZ) reported a net loss of $9.2M while operations used $6.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.